Dual-time-point [18F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapy
Solfrid Thunold, Eivor Hernes, Lars Tore Gyland Mikalsen, Saima Farooqi et autres
0 citationsEJNMMI Research
Åslaug Helland
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
527Publications signalées
12440Citations signalées
4Affiliations récentes
Institutions déclarées
Domaines associés
Lung Cancer Treatments and MutationsCancer Genomics and DiagnosticsCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentLung Cancer Research Studies
Publications récentes
Towards an ecosystem of clinical decision support tools for precision cancer medicine
Sigve Nakken, Anders Edsjö, Janne Lehtiö, Vigdis Nygaard et autres
0 citationsnpj Precision Oncology
ctDNA-Based MRD Detection in Stage III NSCLC Treated With Chemoradiotherapy and Durvalumab
Henrik Horndalsveen, Vilde Drageset Haakensen, Tesfaye Madebo, Bjørn Henning Grønberg et autres
0 citationsJournal of Thoracic Oncology
DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients
Chao Chen, J H Cheng, Ruili Hou, Xiaoyuan Zheng et autres
0 citationsMolecular Oncology
Young-onset colorectal cancer (YOCRC) in the nationwide precision oncology trial IMPRESS-Norway.
Sebastian Meltzer, Hege Elvebakken, Eli Sihn Steinskog, Irja Alida Oppdal et autres
0 citationsJournal of Clinical Oncology
NorTrials drives growth in Norwegian clinical trials
Peder L. Myhre, Åslaug Helland, Kjell‐Morten Myhr, Jan Gunnar Skogås et autres
0 citationsTidsskrift for Den norske legeforening
The impact of Norway’s equitable, nationwide implementation of comprehensive genomic profiling in advanced cancer: results from the first 1,964 patients
I. Dyvik, Daniel Vodák, Laxmi Silwal-Pandit, Kristine Øverås Aasebø et autres
0 citationsSSRN Electronic Journal
A comprehensive assessment of the existing landscape of personalized cancer medicine in the European Union, on behalf of the PCM4EU consortium
Soemeya F. Haj Mohammad, Hilleke E. Hulshoff Pol, Eduard Vrdoljak, Ulrik Lassen et autres
1 citationESMO Open
219P Benchmarking state-of-the-art deep learning models for tumor-infiltrating lymphocytes (TILs) quantification
Masoud Tafavvoghi, Fakher Rahim, Sigve Andersen, Erna‐Elise Paulsen et autres
0 citationsESMO Real World Data and Digital Oncology
Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab
Henrik Horndalsveen, Vilde Drageset Haakensen, Tesfaye Madebo, Bjørn Henning Grønberg et autres
2 citationsFrontiers in Oncology
Too much or too little? The trajectory of systemic anti-cancer treatment throughout the last year of life of lung cancer patients in Norway
Steinar Solberg, Kathinka Schmidt Slørdahl, Marianne Aanerud, Odd Terje Brustugun et autres
0 citationsBJC Reports
EP.01.09 NSCLC Epidemiology and Survival in Denmark, Finland, and Norway: A Decade of Real-World Insights From the LANDSCAPE Study
Aija Knuuttila, Edyta Maria Urbanska, Jolanta Hansen, O. Hölsä et autres
0 citationsJournal of Thoracic Oncology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.